New Crown Global Traceability Research China partly announced: Some suspected positive samples were tested earlier than the first case in Wuhan

This article is reproduced from the WeChat official account of "Daily Economic News"
.

On June 8th, the Health China WeChat public account released the SARS-CoV-2 global traceability study convened by the World Health Organization: China Part-WHO-China Joint Research Report
.

In July 2020, the WHO and China began to carry out the basic work of virus traceability research
.

The WHO Secretariat and the Chinese government have jointly established an international multidisciplinary team to design, support and carry out a series of studies to assist in tracking the source of SARS-CoV-2 and the way it spreads to humans
.

The work of the United International team will lay the foundation for traceability in other regions
.

Therefore, the global traceability work will not be restricted by any location.
With the continuous accumulation of evidence and the continuous development of scientific hypotheses, the global traceability work may change geographically
.

The overall results and findings of the study will help strengthen the global prevention and response to SARS-CoV-2 and new zoonotic diseases of similar origin
.

The joint international research team consists of 17 Chinese experts and 17 international experts from other countries, the World Health Organization, the Global Outbreak Alert and Response Network (GOARN), and the World Organization for Animal Health (OIE)
.

The Food and Agriculture Organization of the United Nations (FAO) participated in this traceability work as an observer
.

After holding several online video conferences, the joint research will be conducted in Wuhan, China from January 14 to February 10, 2021, for a period of 28 days
.

The research team reviewed the work progress of Chinese experts in the following three fields in the first phase through three working groups: epidemiology, animal and environment, molecular epidemiology and bioinformatics
.

The results of the joint study: Epidemiology through the early traceability of the incidence monitoring data Influenza-like disease (ILI) and severe acute respiratory disease (SARI) monitoring combined with appropriate laboratory confirmation, is a measure of the impact of influenza and other respiratory viruses on the population Standard measures
.

In order to determine the possible impact of the pathogen of COVID-19 on the incidence of the above two diseases in the months before the outbreak of COVID-19, we monitored the adult sentinel surveillance data of ILI in a hospital in Wuhan and SARI surveillance in a provincial hospital in Hubei Province The data was reviewed
.

According to the national ILI sentinel monitoring data in Wuhan, Hubei and the surrounding six provinces and influenza activities confirmed by related laboratories, at the end of 2019, there was a significant increase in ILI among children and adults in Wuhan, other cities in Hubei and the surrounding six provinces
.

Although this may be due to the simultaneous increase in laboratory-confirmed influenza activity, the joint team recommends using time series analysis to further explore the weekly ILI trend in 2019 compared with previous years
.

The analysis of antipyretics, cold medicines and cough medicines purchased in retail pharmacies does not indicate early SARS-CoV-2 activities in the community
.

The joint team recommends reviewing the weekly pharmacy purchases from September to December in 2016, 2017, 2018, and 2019 to look for signs of increased purchases from September to December 2019 compared to the same period in the previous year
.

If any signal is recognized, it is recommended to continue analyzing the spatio-temporal clusters
.

Through the early traceability of preserved laboratory samples and other resources, when retrospectively testing more than 4,500 research project samples in the second half of 2019 preserved in hospitals in Wuhan, other regions of Hubei Province and other provinces, no SARS was found -CoV-2
.

This work can be extended to other blood centers in China and other parts of the world.
The time is concentrated within 6 months before the first case is detected locally.
It is best to use a systematically designed random selection sample and the same laboratory testing methods
.

Samples of blood donors from other parts of China who have not found COVID-19 cases before the first few months of 2020 can be used as a control group
.

Through the early traceability work of mortality research, the monitoring data of all causes of death and pneumonia deaths in Wuhan City and Hubei Province except Wuhan did not show evidence of unexpected fluctuations in the death trend during July-December 2019, and it cannot indicate that it occurred before December 2019.
The spread of SARS-CoV-2 in the population
.

Nevertheless, it cannot be ruled out that SARS-CoV-2 is spreading at a low level in the population, because population-level mortality changes are unlikely to be sensitive enough to detect this
.

In view of the time lag from the start of infection to COVID-19-related deaths, the rapid increase in all-cause mortality and pneumonia-specific deaths in the third week of 2020 indicates that the virus has spread widely among the Wuhan population in the first week of 2020
.

In the population of Hubei Province outside Wuhan, the sharp increase in mortality occurred after 1-2 weeks, which shows that the epidemic in Wuhan is earlier than that in other areas of Hubei Province and other provinces
.

The joint team recommends that the scope of the mortality review be expanded to include other provinces where phylogenetic analysis found early epidemic clusters and compare them with other provinces and cities in China
.

A clinical review of potential cases in Wuhan in October and November 2019.
A total of 233 medical institutions in Wuhan have searched for four diseases (fever, acute respiratory disease, influenza-like disease and " One of the patients with unexplained pneumonia) who came to medical institutions to see a total of 76,253 medical records
.

At the beginning of December 2019, the ARI (and ILI and fever) of the 60-year-old age group increased compared to the previous period
.

After review by the clinical teams of various medical institutions, 92 out of 76,253 people are considered to be clinically compatible with the disease caused by SARS-CoV-2 infection
.

In January 2021, 67 out of 92 cases (excluding death cases, rejected or unavailable cases) will be collected The blood was collected, and the SARS COV-2 antibody test was carried out using colloidal gold method, and the results were all negative
.

After subsequent re-examination by external multidisciplinary clinical experts, it was determined that 92 cases were not eligible for SARS-CoV-2 infection
.

Based on the December 2019 epidemic There was no evidence of SARS-CoV-2 infection in potential cases in Wuhan within two months before the outbreak.
The international joint expert team believes that the possibility of partial transmission cannot be ruled out at this stage
.

In addition, 12 months after the outbreak, an investigation will be conducted in 2019 There are also limitations to serological testing methods for the possibility of transmission within a few months of the end of the year
.
The
joint team recommends further review of the methods used to identify and describe the characteristics of cases in retrospective clinical studies, including 92 cases initially identified that may be consistent with COVID-19 diagnosis In order to find the characteristics of COVID-19 (such as cluster disease) that have not been confirmed before, as well as other possible mild cases
.

In view of the increase in ARI in the elderly at the beginning of December 2019, further joint review should be conducted ARI data
.

The 67 specimens obtained in the clinical review should be further tested and compared with the 174 case samples confirmed since December 2019 and any other relevant samples after re-examination
.

This should be linked to a new method of serological testing through historical samples collected from blood banks
.

A retrospective analysis of cases reported by the National Notifiable Disease Reporting System In early December 2019, an outbreak caused by SARS-CoV-2 infection occurred in Wuhan
.

A total of 174 cases of COVID-19 (100 laboratory confirmed cases and 74 clinically confirmed cases) were found with onset in December 2019
.

Only the more serious cases that went to the medical system were confirmed
.

Other mild (and asymptomatic) cases co-exist with confirmed cases, but there is currently no information on these milder cases, which may be a supplement to the epidemiology of the early outbreak
.

Many early cases are related to the South China Seafood Market, but there are also similar numbers of cases related to other markets, and some cases are not related to any market
.

The spread in the wider community in December can explain the cases that are not related to the South China Seafood Market.
In addition, there are early cases that are not related to the South China Seafood Market, which can indicate that the South China Seafood Market is not the origin of the epidemic
.

However, other unconfirmed milder cases may provide a link between the South China Seafood Market and early cases, which were previously thought to have no obvious link to the market
.

Therefore, it is not yet possible to draw definitive conclusions about the role of the South China Seafood Market in the origin of the epidemic or how the infection was introduced to the market
.

In view of the limited time during the visit to Wuhan in January and February 2021, a further joint review of 174 confirmed cases should be conducted, including analysis of the clinical and demographic characteristics and risk factors of the cases
.

Whether to re-examine these patients in person depends on the results of the joint review
.

The joint team also recommends reviewing the information of other patients who were reported as potential COVID-19 cases in December 2019 to understand whether these cases are previously unconfirmed COVID-19 cases, and whether the SARS-CoV-2 outbreak is being confirmed for the first time During the period, the infection situation in the local population will provide any additional information Molecular epidemiology Since most of the new viruses are derived from animals, it is necessary to understand the variety of viruses carried by animal reservoirs in order to understand the process leading to virus spillage and global spread Sex and evolution, the interaction between animals, the environment, and humans, and the factors that form effective human-to-human transmission
.

The virus that can cause a global pandemic must be highly adapted to the human environment
.

This adaptation may be acquired suddenly or gradually through multiple steps, and each step is driven by natural selection
.

Therefore, the traceability of SARS-CoV-2 should focus on two stages
.

The first stage involves the circulation of the virus in animal hosts (such as bats, pangolins, or other wild or domestic animals) before zoonotic transfer occurs
.

In this evolutionary process, various animal species may become reservoirs
.

The ancestor strain of SARS-CoV-2 may have acquired the ability to infect humans during its cycle
.

The discovery of a virus with a highly homologous sequence to the SARS-CoV-2 virus indicates that SARS-CoV-2 may originate from zoonotic transmission, but its reservoir remains to be ascertained
.

The second stage involves the evolution of SARS-CoV-2 in the population spread after zoonotic transfer
.

The possibility of this animal-to-human spillage increases with the frequency and intensity of animal-human contact
.

Spills may occur repeatedly, but if the viral genome in the reservoir needs to be further adapted to achieve effective and sustained transmission, this early spill may not be detected
.

Once viruses with pandemic potential evolve or overflow, they will gain the ability to spread, resulting in a large number of adaptively mutated virus strains appearing in people in different regions, thus triggering the COVID-19 pandemic
.

Animal genome data The evidence from investigations and targeted studies so far shows that the coronavirus most closely related to SARS-CoV-2 has been found in bats and pangolins
.

The genetic sequence of the sample virus and SARS-CoV-2 has a high degree of similarity, suggesting that the above-mentioned mammals may be the reservoir of the virus that causes COVID-19
.

However, so far, the similarity between the virus found in 99 species and SARS-CoV-2 is not enough to make it the direct ancestor of SARS-CoV-2
.

In addition to these findings, the high susceptibility of mink and cats to SARS-CoV-2 suggests that there may be other animal species (musteles or cats, among others) as potential reservoirs
.

Comparing the data in the sequence database with the data in the investigation of potential reservoir species, it is found that the collection of specimens for these potential reservoir species is seriously insufficient
.

The joint team of analysis of viral genomes and early epidemiological data of the pandemic reviewed the data collected through the China National Bioinformatics Center in its comprehensive database containing all available coronavirus sequences and metadata
.

All sequence data of samples collected in December 2019 and January 2020 were selected for in-depth analysis, and the diversity of the virus in the first phase of the pandemic was reviewed
.

For the cases found in Wuhan, China, after linking the data with the epidemiological background, the cases with onset before December 31 were selected
.

The final analysis showed that among the cases exposed to the South China Seafood Market, several cases had the same viral genome, indicating that these cases may be part of a cluster of cases
.

However, the sequence data also showed that there was a certain amount of virus diversity at the beginning of the pandemic in Wuhan, indicating that there is an unsampled transmission chain outside the South China seafood market group
.

Judging from the epidemiological parameters of exposure to raw meat or fur animals, there is no obvious clustering of cases
.

Estimate the time to the nearest common ancestor based on the early sequence data.
In addition, the time from the SARS-CoV-2 sequence to the nearest common ancestor (tMRCA) in the final data set is estimated through analysis and compared with the results of previous studies
.

Such a tMRCA analysis can be considered as an estimate and cannot provide a definitive proof of the time of origin
.

Analysis of molecular sequence data indicates that the start of the pandemic may be a month before mid-December
.

The estimated time points vary from late September to early December, but most of the estimated points are between mid-November and early December
.

SAES-CoV-2 Literature Review: Early Discovery Finally, the data in the published literature showing the early circulation of SARS-CoV-2 was reviewed
.

These studies from different countries have shown that the circulation of SARS-CoV-2 is several weeks earlier than the initial detection of the case
.

Some suspected positive samples were tested even earlier than the first case in Wuhan, suggesting that there may be missed diagnosis in other areas
.

But so far, the quality of research is still very limited
.

Nevertheless, it is important to investigate these potential early events
.

Animal and environmental research People have discovered phylogenetic coronaviruses related to SARS-CoV-2 in different animals, including chrysanthemum bats and pangolins
.

However, bat samples taken in Hubei Province did not find evidence of the existence of SARS-CoV-2, and samples of wild animals across China have not yet found the existence of SARS-CoV-2
.

A total of more than 80,000 specimens of wild animals, livestock and poultry were collected in 31 provinces in China
.
No positive results for SARS-CoV-2 antibodies and nucleic acids were found before and after the SARS-CoV-2 outbreak .

Through extensive testing of animal products in the South China Seafood Market, no evidence of animal infection was found
.

Environmental sampling after the closure of the Huanan Seafood Market showed that 73 of the 923 environmental samples were positive, indicating that SARS-CoV-2 contamination is widespread on the surface, which is consistent with the introduction of the virus through infected persons, infected animals, and contaminated products
.

The supply chain of the South China Seafood Market includes cold chain products and animal products from 20 countries.
Some of these countries have reported positive SARS-CoV-2 samples before the end of 2019, or have been found to be closely related to SARS-CoV-2 Virus
.

There is evidence that some farmed wild animal species products sold in the market are susceptible to SARS-CoV-2.
However, in this study, none of the animal samples collected on the market had positive results
.

Cold chain products have not been tested
.

However, these research results do raise the possibility that there may be different channels of introduction, and emphasize the need for careful traceability and sample testing of these supply chains
.

SARS-CoV-2 can survive the conditions of frozen food, packaging and cold chain products
.

The index cases in the recent outbreak in China are related to the cold chain
.

Studies have shown that viruses can survive for a long time at low temperatures and can therefore be carried over long distances on frozen products
.

The viability of the virus at different temperatures is currently being further studied
.

There are a large number of stalls selling cold chain products in the South China Seafood Market
.

Epidemiological studies have shown that the relative risk of cases in stalls with cold chain goods is higher than that of stalls without cold chain goods
.

Further analysis is needed to determine the spatio-temporal correspondence and correct the potential bias in sampling
.

Other studies that should be carried out include tracing cold chain goods imported from areas where SARS-CoV-2 positive samples were reported before the end of 2019, and tracing the process of frozen wild animal products from the supply farm to the South China seafood market through interviews with suppliers
.

In other countries that supply cold chain products to China, evidence of SARS-CoV-2 has been found on packaging and products
.

There is evidence that there are early clusters of cases in other countries that provide cold chain products to China
.

Another issue is to investigate the cold chain or refrigerated supply chain in areas where SARS-CoV-2 positive samples have been reported before the end of 2019 or in countries where SARS-related coronaviruses have been found in animals (such as Southeast Asian countries)
.

At the same time, it is necessary to distinguish the role of cold chain in the imported virus from abroad and the epidemic situation in the market itself.
The latter may be that the infected person has contaminated the product
.

Source: Healthy China End's previous selection of onlookers will shut out the gods of death! "Nature Communications": Human life limit is between 120-150 years old.
Isn't it good to brush your teeth? The new study found that oral bacteria may activate the oncogene hot text "Three Children", this time it is "actual"! The spring of assisted reproduction is here! The first case in the world! After colorectal cancer patients received mRNA vaccine, cytokine storm appeared, or related to anti-PD-1 treatment, Nature's three consecutive heavyweights! Seeing through the "trick" of cancer cells, bringing new hope to patients with colorectal cancer Medical immunotherapy | Biosimilars | Vaccines | Resistance | Drug targets | Healthy life | Pharmaceutical company news | Drug inventory | Pharmaceutical technology | Drug side effects Basic Research/Translational Medicine Leukemia| Lung Cancer| Gastric Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Diseases| Neurodegenerative Diseases| Intestinal Microbiological Medical Devices/Biotechnology In Vitro Diagnosis| Medical Devices| Bio-Nano| 3D Print|Gene detection|Single cell sequencing|Gene editing|Assisted reproduction|Artificial intelligence|Precision medicine policyAnticancer drugs|4+7 volume procurement|Consumables|Recording system|Registrant system|Health China|New edition of basic medicine catalog|AI Medical equipment | Telemedicine | Same stock market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D Investment | Acquisitions | Market & Consumption